Last reviewed · How we verify
Gemcitabine + cisplatin + S-1
This combination uses gemcitabine and cisplatin as DNA-damaging chemotherapy agents alongside S-1, an oral fluoropyrimidine, to inhibit cancer cell proliferation and survival through multiple pathways.
This combination uses gemcitabine and cisplatin as DNA-damaging chemotherapy agents alongside S-1, an oral fluoropyrimidine, to inhibit cancer cell proliferation and survival through multiple pathways. Used for Gastric cancer or gastroesophageal junction cancer (Phase 3 development).
At a glance
| Generic name | Gemcitabine + cisplatin + S-1 |
|---|---|
| Also known as | Background Gemcitabine-based Chemotherapy Regimen., This regimen is not allowed for countries in the European Union. |
| Sponsor | AstraZeneca |
| Drug class | Chemotherapy combination (nucleoside analog + platinum agent + fluoropyrimidine) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing chain termination. Cisplatin is a platinum-based alkylating agent that forms DNA cross-links, preventing replication. S-1 is a combination of tegafur (a prodrug of 5-fluorouracil), gimeracil (dihydropyrimidine dehydrogenase inhibitor), and oteracil (orotate phosphoribosyltransferase inhibitor) that enhances fluoropyrimidine activity by inhibiting its degradation and reducing gastrointestinal toxicity.
Approved indications
- Gastric cancer or gastroesophageal junction cancer (Phase 3 development)
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Nausea and vomiting
- Diarrhea
- Nephrotoxicity
- Peripheral neuropathy
Key clinical trials
- Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (PHASE3)
- Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) (PHASE3)
- A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma (PHASE2)
- Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal Carcinoma
- A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors (PHASE2)
- Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer (PHASE2)
- Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma (PHASE2)
- Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gemcitabine + cisplatin + S-1 CI brief — competitive landscape report
- Gemcitabine + cisplatin + S-1 updates RSS · CI watch RSS
- AstraZeneca portfolio CI